Brryh, either those who are interested in antibiotic resistance or those who are interested in neurodegeneration. I think that the issues with antibiotic resistance are clearer ( = a lot of publications over many years) than those Prof. Masters has done ( = failed studies, unfortunately at least earlier, no new publications).
IMO, we = present investors are on the same side as the administration with their shares and options. The stock price has been manipulated for years. Nobody who understands the value of PBT2 in the antibiotic resistance world will sell 10% of PBT2 with a few million.
Not many hours to the opening of Sidney. Interesting morning. I may become disappointed, but until morning there is some hope.
News: ATH Alterity Therapeutics Seeks Trading Halt, page-19
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $1.404K | 280.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 64303651 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 39348359 | 23 |
View Market Depth
| Last trade - 12.04pm 11/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |